Categories Uncategorized

Brain Scientific Inc. (BRSF) Poised to Benefit as Rapidly Growing Brain-Computer Interface Field Drives EEG Growth

  • Brain-Computer Interface (“BCI”) market is expanding rapidly, expected to double to USD 406 billion by 2026
  • BCI technology, designed to acquire brain signals, analyze and translate them into commands, is one of key driving forces behind EEG technology growth
  • Brain Scientific appears poised to capitalize on this novel technology as its applications expand from medical settings to training, consumer engagement, entertainment, and more

The Brain-Computer Interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. As the provider of EEG technology, Brain Scientific (OTCQB: BRSF) appears well placed to leverage this rapid growth of the industry expected to double in size by 2026 (https://ibn.fm/F5LOs). 

BCI technology refers to solutions that record the brain signal from the surface of the cortex, using sensors placed over the scalp or signaling devices implanted in the brain. As a promising approach to overcome paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector, BCI can provide opportunities for motor rehabilitation from a number of conditions, including spinal cord injury, traumatic brain injury, and stroke (https://ibn.fm/C9Dom). This powerful technology can even help patients who lost the ability to speak to communicate. A recent study reports the first patient ever to produce whole words via a computer that decodes his brain’s messages through electrodes implanted in his brain (https://ibn.fm/gr3j7). 

Enabling advances never possible before, the BCI space is expanding rapidly, and EEG is an essential part of that landscape. Recent market research reveals that the BCI market is expected to grow at a 12.4% CAGR over the next five years, reaching $409.3 million by 2026 — more than double compared to $203 million reported in 2020. Main growth drivers include swelling demand from healthcare, entertainment, gaming, communication, and control.

Traditionally, EEG-based BCI technology has been geared towards medical applications where it was utilized to help disabled patients to interact with the external world. However, with a shift of focus towards people with normal health, the technology is no longer constrained to medical settings only. For example, training — including athletic, military, and occupational — and fields such as consumer engagement and entertainment are becoming target groups that would likely benefit from using EEG-based BCI systems (https://ibn.fm/oV87E).

As the application space for EEG-based BCI solutions expands, Brain Scientific appears poised for rapid growth. With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the Company appears well-placed within the growing brain monitoring space. Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the ground-breaking technology that aim to enable what was inconceivable until recently. 

For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…

14 hours ago

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…

16 hours ago

Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The…

2 days ago

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight…

3 days ago

Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…

6 days ago

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and…

6 days ago